Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689467 | 0.84 | TTR (0.41) | CYP2A6ALDH1A1TTRALBMEN1 | |
| SCHEMBL916379 | 0.84 | TTR (0.41) | CYP2A6ALDH1A1TTRALBMEN1 | |
| SCHEMBL27748133 | 0.84 | NOS1 (0.39) | CYP2A6ALDH1A1IDH1NOS3NOS1 | |
| SCHEMBL11982666 | 0.81 | CYP2A6 (0.50) | CYP2A6ALDH1A1IDH1NOS3NOS1 | |
| SCHEMBL22477339 | 0.81 | CYP2A6 (0.39) | CYP2A6ALDH1A1IDH1NOS3NOS1 | |
| SCHEMBL5898258 | 0.79 | TTR (0.39) | CYP2A6ALDH1A1IDH1NOS3NOS1 | |
| SCHEMBL7896912 | 0.79 | LOXL2 (0.48) | CYP2A6ALDH1A1IDH1NOS3NOS1 | |
| SCHEMBL6742065 | 0.79 | CYP2A6 (0.38) | CYP2A6ALDH1A1IDH1NOS3NOS1 | |
| SCHEMBL1484448 | 0.79 | CYP2A6 (0.38) | CYP2A6ALDH1A1IDH1NOS3NOS1 | |
| SCHEMBL501516 | 0.79 | CYP2A6 (0.38) | CYP2A6ALDH1A1IDH1NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| WO-2021228992-A1 | NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY | RIGSHOSPITALET (DK) | 2021-11-18 | — | — | WO | disclosed |
| EP-3909944-A1 | NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY | Rigshospitalet (DK) | 2021-11-17 | — | — | EP | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| EP-2167476-B1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RES INST CHEM TECH (KR) | 2015-02-25 | — | — | EP | disclosed |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-8354421-B2 | HIV reverse transcriptase inhibitors | KOREA RESEARCH INSITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-01-15 | — | — | US | disclosed |
| US-8354421-B2 | HIV reverse transcriptase inhibitors | KOREA RESEARCH INSITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-01-15 | — | — | US | disclosed |
| US-8354421-B2 | HIV reverse transcriptase inhibitors | KOREA RESEARCH INSITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-01-15 | — | — | US | disclosed |
| WO-2008016522-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016522-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-1151990-A1 | Substituted N-arylmethylamino derivatives of cyclobutene-3, 4-diones | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-11-07 | — | — | EP | disclosed |
| EP-0934257-A1 | SUBSTITUTED N-ARYLMETHYLAMINO DERIVATIVES OF CYCLOBUTENE-3,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5780505-A | ADMINISTERING AS SMOOTH MUSCLE RELAXANT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998002413-A1 | SUBSTITUTED N-ARYLMETHYLAMINO DERIVATIVES OF CYCLOBUTENE-3,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| WO-1989004305-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CYP2A6 1273/4885ALDH1A1 1320/4885IDH1 3017/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | CYP2A6 1273/4885ALDH1A1 1320/4885IDH1 3017/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CYP2A6 1273/4885ALDH1A1 1320/4885IDH1 3017/4885 |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLR1E, POLR2H | CYP2A6 1885/4885ALDH1A1 1800/4885IDH1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.